Original article
Clinical Outcomes in Patients With Psoriasis Following Discontinuation of Efalizumab Due to Suspension of Marketing Authorization
Evolución clínica de los pacientes psoriásicos tratados con efalizumab al suspender el fármaco
O. Baniandrés
, A. Pulido, C. Silvente, R. Suárez, P. Lázaro
Autor para correspondencia
Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Leído
6596
Vecesse ha leído el artículo
2704
Total PDF
3892
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 67 | 32 | 99 |
| 2025 5 | 113 | 32 | 145 |
| 2025 4 | 95 | 22 | 117 |
| 2025 3 | 99 | 18 | 117 |
| 2025 2 | 99 | 45 | 144 |
| 2025 1 | 82 | 28 | 110 |
| 2024 12 | 87 | 23 | 110 |
| 2024 11 | 84 | 53 | 137 |
| 2024 10 | 61 | 40 | 101 |
| 2024 9 | 51 | 28 | 79 |
| 2024 8 | 93 | 53 | 146 |
| 2024 7 | 57 | 39 | 96 |
| 2024 6 | 68 | 40 | 108 |
| 2024 5 | 49 | 32 | 81 |
| 2024 4 | 50 | 27 | 77 |
| 2024 3 | 46 | 34 | 80 |
| 2024 2 | 46 | 37 | 83 |
| 2024 1 | 45 | 40 | 85 |
| 2023 12 | 51 | 33 | 84 |
| 2023 11 | 52 | 26 | 78 |
| 2023 10 | 44 | 33 | 77 |
| 2023 9 | 54 | 26 | 80 |
| 2023 8 | 28 | 22 | 50 |
| 2023 7 | 64 | 63 | 127 |
| 2023 6 | 59 | 30 | 89 |
| 2023 5 | 45 | 25 | 70 |
| 2023 4 | 31 | 34 | 65 |
| 2023 3 | 27 | 14 | 41 |
| 2023 2 | 23 | 18 | 41 |
| 2022 1 | 27 | 27 | 54 |
| 2022 12 | 33 | 44 | 77 |
| 2022 11 | 15 | 23 | 38 |
| 2022 10 | 18 | 19 | 37 |
| 2022 9 | 14 | 40 | 54 |
| 2022 8 | 17 | 42 | 59 |
| 2022 7 | 15 | 34 | 49 |
| 2022 6 | 14 | 27 | 41 |
| 2022 5 | 20 | 39 | 59 |
| 2022 4 | 28 | 39 | 67 |
| 2022 3 | 26 | 58 | 84 |
| 2022 2 | 19 | 22 | 41 |
| 2021 1 | 27 | 47 | 74 |
| 2021 12 | 28 | 39 | 67 |
| 2021 11 | 25 | 45 | 70 |
| 2021 10 | 24 | 59 | 83 |
| 2021 9 | 28 | 48 | 76 |
| 2021 8 | 14 | 23 | 37 |
| 2021 7 | 20 | 37 | 57 |
| 2021 6 | 24 | 23 | 47 |
| 2021 5 | 23 | 33 | 56 |
| 2021 4 | 40 | 48 | 88 |
| 2021 3 | 51 | 30 | 81 |
| 2021 2 | 41 | 26 | 67 |
| 2020 1 | 22 | 13 | 35 |
| 2020 12 | 20 | 17 | 37 |
| 2020 11 | 28 | 21 | 49 |
| 2020 10 | 18 | 8 | 26 |
| 2020 9 | 30 | 7 | 37 |
| 2020 8 | 21 | 33 | 54 |
| 2020 7 | 13 | 8 | 21 |
| 2020 6 | 21 | 22 | 43 |
| 2020 5 | 26 | 19 | 45 |
| 2020 4 | 25 | 19 | 44 |
| 2020 3 | 25 | 20 | 45 |
| 2020 2 | 3 | 3 | 6 |
| 2020 1 | 0 | 5 | 5 |
| 2019 12 | 0 | 6 | 6 |
| 2019 11 | 0 | 5 | 5 |
| 2019 10 | 0 | 3 | 3 |
| 2019 8 | 0 | 4 | 4 |
| 2019 7 | 0 | 2 | 2 |
| 2019 6 | 0 | 2 | 2 |
| 2019 5 | 1 | 36 | 37 |
| 2019 4 | 0 | 2 | 2 |
| 2019 3 | 0 | 24 | 24 |
| 2019 2 | 0 | 3 | 3 |
| 2018 3 | 0 | 2 | 2 |
| 2018 2 | 12 | 2 | 14 |
| 2018 1 | 16 | 5 | 21 |
| 2017 12 | 12 | 6 | 18 |
| 2017 11 | 14 | 5 | 19 |
| 2017 10 | 15 | 7 | 22 |
| 2017 9 | 13 | 8 | 21 |
| 2017 8 | 16 | 7 | 23 |
| 2017 7 | 15 | 0 | 15 |
| 2017 6 | 39 | 5 | 44 |
| 2017 5 | 17 | 7 | 24 |
| 2017 4 | 12 | 15 | 27 |
| 2017 3 | 17 | 8 | 25 |
| 2017 2 | 19 | 8 | 27 |
| 2016 1 | 8 | 4 | 12 |
| 2016 12 | 21 | 8 | 29 |
| 2016 11 | 17 | 6 | 23 |
| 2016 10 | 21 | 5 | 26 |
| 2016 9 | 31 | 8 | 39 |
| 2016 8 | 29 | 6 | 35 |
| 2016 7 | 31 | 7 | 38 |
| 2016 6 | 13 | 7 | 20 |
| 2016 5 | 9 | 7 | 16 |
| 2016 4 | 3 | 1 | 4 |
| 2016 3 | 6 | 0 | 6 |
| 2016 2 | 5 | 2 | 7 |
| 2015 1 | 9 | 5 | 14 |
| 2015 12 | 8 | 1 | 9 |
| 2015 11 | 7 | 0 | 7 |
| 2015 10 | 11 | 3 | 14 |
| 2015 9 | 12 | 0 | 12 |
| 2015 8 | 20 | 3 | 23 |
| 2015 7 | 38 | 4 | 42 |
| 2015 6 | 25 | 9 | 34 |
| 2015 5 | 50 | 14 | 64 |
| 2015 4 | 29 | 4 | 33 |
| 2015 3 | 27 | 7 | 34 |
| 2015 2 | 26 | 11 | 37 |
| 2015 1 | 11 | 12 | 23 |
| 2014 12 | 23 | 24 | 47 |
| 2014 11 | 14 | 10 | 24 |
| 2014 10 | 21 | 16 | 37 |
| 2014 9 | 16 | 11 | 27 |
| 2014 8 | 36 | 17 | 53 |
| 2014 7 | 27 | 18 | 45 |
| 2014 6 | 38 | 10 | 48 |
| 2014 5 | 33 | 10 | 43 |
| 2014 4 | 38 | 6 | 44 |
| 2014 3 | 37 | 14 | 51 |
| 2014 2 | 26 | 12 | 38 |
| 2014 1 | 31 | 16 | 47 |
| 2013 12 | 31 | 9 | 40 |
| 2013 11 | 27 | 12 | 39 |
| 2013 10 | 26 | 15 | 41 |
| 2013 9 | 33 | 11 | 44 |
| 2013 8 | 15 | 24 | 39 |
| 2013 7 | 30 | 52 | 82 |
| 2013 6 | 20 | 27 | 47 |
| 2013 5 | 23 | 18 | 41 |
| 2013 4 | 19 | 21 | 40 |
| 2013 3 | 20 | 18 | 38 |
| 2013 2 | 10 | 13 | 23 |
Mostrar todo
